

THE PRESENT AND FUTURE

JACC SCIENTIFIC EXPERT PANEL

Clinical Genetic Testing for Familial Hypercholesterolemia

JACC Scientific Expert Panel



Amy C. Sturm, MS,^{a,*} Joshua W. Knowles, MD, PhD,^{b,c,*} Samuel S. Gidding, MD,^{d,*} Zahid S. Ahmad, MD,^e Catherine D. Ahmed, MBA,^c Christie M. Ballantyne, MD,^f Seth J. Baum, MD,^{c,g} Mafalda Bourbon, PhD,^{h,i} Alain Carrié, MD, PhD,^j Marina Cuchel, MD, PhD,^k Sarah D. de Ferranti, MD, MPH,^l Joep C. Defesche, PhD,^m Tomas Freiburger, MD, PhD,^{n,o} Ray E. Hershberger, MD,^p G. Kees Hovingh, MD, PhD,^q Lala Karayan, MPH,^c Johannes Jacob Pieter Kastelein, MD, PhD,^q Iris Kindt, MD, MPH,^c Stacey R. Lane, JD, MBE,^c Sarah E. Leigh, MSc, PhD,^r MacRae F. Linton, MD,^s Pedro Mata, MD, PhD,^t William A. Neal, MD,^{c,u} Børge G. Nordestgaard, MD, DMSc,^{v,w} Raul D. Santos, MD, PhD,^x Mariko Harada-Shiba, MD, PhD,^y Eric J. Sijbrands, MD, PhD,^z Nathan O. Stitziel, MD, PhD,^{aa} Shizuya Yamashita, MD, PhD,^{bb,cc} Katherine A. Wilemon, BS,^{c,†} David H. Ledbetter, PhD,^{a,†} Daniel J. Rader, MD,^{c,dd,†}

Convened by the Familial Hypercholesterolemia Foundation

JACC JOURNAL CME/MOC/ECME

This article has been selected as the month's JACC CME/MOC/ECME activity, available online at <http://www.acc.org/jacc-journals-cme> by selecting the JACC Journals CME/MOC/ECME tab.

Accreditation and Designation Statement

The American College of Cardiology (ACC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The ACC designates this Journal-based CME activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this JACC Journal CME/MOC activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel will be accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME) and the European Board for Accreditation in Cardiology (EBAC) have recognized each other's accreditation systems as substantially equivalent. Apply for credit through the post-course evaluation. While offering the credits noted above, this program is not intended to provide extensive training or certification in the field.

Method of Participation and Receipt of CME/MOC/ECME Certificate

To obtain credit for JACC CME/MOC/ECME, you must:

1. Be an ACC member or JACC subscriber.
2. Carefully read the CME/MOC/ECME-designated article available online and in this issue of the *Journal*.

3. Answer the post-test questions. A passing score of at least 70% must be achieved to obtain credit.
4. Complete a brief evaluation.
5. Claim your CME/MOC/ECME credit and receive your certificate electronically by following the instructions given at the conclusion of the activity.

CME/MOC/ECME Objective for This Article: Upon completion of this activity, the learner should be able to: 1) recognize the benefits of genetic testing for familial hypercholesterolemia; 2) apply genetic testing results in clinical care for familial hypercholesterolemia; and 3) demonstrate understanding of alternative etiologies for a familial hypercholesterolemia phenotype in the setting of negative genetic testing for FH.

CME/MOC/ECME Editor Disclosure: JACC CME/MOC/ECME Editor Raganendra R. Baliga, MD, FACC, has reported that he has no financial relationships or interests to disclose.

Author Disclosures: Ms. Sturm has served on scientific advisory boards for Clear Genetics and Genome Medical. Dr. Knowles has served as the chief medical advisor for the Familial Hypercholesterolemia Foundation; and has received funding from an American Heart Association National Innovative Research Award and the Doris Duke Charitable Trust. Dr. Gidding has served as a consultant for Regenxbio. Dr. Ahmad has performed research for the National Institutes of Health and Regeneron; has served as a speaker for Amgen, Sanofi, and Akcea; and has served on advisory boards for Sanofi and Akcea. Dr. Ballantyne has received grant/research support (all paid to institution, not individual) from Abbott Diagnostic, Amarin, Amgen, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostics, and Sanofi-Synthelabo; and has served as a consultant for Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostics, and Sanofi-Synthelabo. Dr. Baum has served on scientific advisory boards, provided consulting, and performed clinical research for Amgen, Sanofi/Regeneron, Esperion, Akcea, AstraZeneca, Boehringer Ingelheim/Lilly, Novo Nordisk, and Gempire; and has served as a speaker for Amgen, Boehringer Ingelheim/



Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.



Lilly, Novo Nordisk, and Aralez. Dr. Bourbon has received research funding from Praxis (Aegerion), Alexion, Regeneron, and Gendiag. Dr. Carrie has received honoraria from Amgen SAS and Alexion Pharma France SAS; and a grant from Alexion Pharma France SAS. Dr. Cuchel has received industry support for the performance of clinical trials from Akcea, Regeneron Pharmaceuticals, and Regenxbio; has served on the speakers bureau for Aegerion Pharmaceuticals; and has received federal funding from the National Heart, Lung, and Blood Institute (HL059407). Dr. de Ferranti has received royalties from UpToDate for topics related to pediatric lipid screening and treatment; and grant funding from the Pediatric Heart Network (no overlap) and the New England Congenital Cardiology Research Foundation (no overlap). Dr. Freiburger has received grants from the Ministry of Health of the Czech Republic (16-29084A and 15-28277A) (all rights reserved). Dr. Hovingh has served as an advisory board member and/or speaker for Pfizer, Regeneron, Sanofi, Amgen, and Aegerion (his institution receives the financial compensation for these services). Dr. Kastelein has provided consulting for Sanofi, Affiris, Akarna Therapeutics, Amgen, CSL Behring, Regeneron, Staten Biotech, Madrigal, The Medicines Company, Kowa, Lilly, Esperion, Gemphire, Ionis Pharmaceuticals, and Akcea Pharmaceuticals. Dr. Linton has performed research for Merck, Amgen, Sanofi, Regeneron, Genzyme, Ionis, the National Institutes of Health (HL116263), FH Foundation CASCADE; and has served as a consultant for Regenxbio. Dr. Mata has received honoraria for advisory boards and research grants from Amgen and Sanofi. Dr. Santos has received honoraria related to consulting, speaker activities, and

research from Amgen, AstraZeneca, Akcea, Biolab, Esperion, Merck, Novo Nordisk, Pfizer, and Sanofi/Regeneron. Dr. Harada-Shiba has received grants from Japan Agency for Medical Research and Development, Japanese Ministry of Health, Labour and Welfare, The Japanese Circulation Society, Aegerion, Astellas Pharm, Takeda, MSD, and Kaneka Medics; and has received honoraria for talks from Astellas, Astellas Amgen, Sanofi, Takeda, MSD, Boehringer Ingelheim, Daiichi-Sankyo, Kaneka Medics, and Kowa. Dr. Sijbrands received a grant from Amgen for scientific research (not drug related). Dr. Yamashita has received research grants from Merck Sharp & Dohme, Bayer, Boehringer Ingelheim, Takeda, Ono, and Astellas; has received consulting fees from Skylight Biotech; and has served on the speakers bureau for Kowa, Merck Sharp & Dohme, Astellas, Astellas-Amgen Biopharma, and Sanofi. Ms. Wilemon has served as the chief executive officer for the Familial Hypercholesterolemia Foundation. Dr. Ledbetter has served as the chief scientific officer for Clear Genetics, Inc. Dr. Rader has served as the chief scientific advisor for the Familial Hypercholesterolemia Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Medium of Participation: Print (article only); online (article and quiz).

CME/MOC Term of Approval

Issue Date: August 7, 2018

Expiration Date: August 6, 2019

From the ^aGenomic Medicine Institute, Geisinger, Danville, Pennsylvania; ^bDepartment of Medicine, Division of Cardiovascular Medicine, and Cardiovascular Institute, Stanford University, Stanford California; ^cThe Familial Hypercholesterolemia Foundation, Pasadena, California; ^dNemours Cardiac Center, A.I. DuPont Hospital for Children, Wilmington, Delaware; ^eDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; ^fDepartment of Medicine, Baylor College of Medicine, Houston, Texas; ^gDepartment of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida; ^hUnidade I&D, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal; ⁱUniversity of Lisbon, Faculty of Sciences, BioISI-Biosystems & Integrative Sciences Institute, Lisboa, Portugal; ^jSorbonne Université and Centre de Génétique Moléculaire et Chromosomique, unité de Génétique de l'Obésité et des dyslipidémies, Hôpital de la Pitié-Salpêtrière, Paris, France; ^kDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; ^lDepartment of Cardiology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts; ^mDepartment of Clinical Genetics, Academic Medical Center at the University of Amsterdam, Amsterdam, the Netherlands; ⁿCentral European Institute of Technology, Masaryk University, Brno, Czech Republic; ^oCentre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic; ^pDepartment of Internal Medicine, Wexner Medical Center at The Ohio State University, Columbus, Ohio; ^qDepartment of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands; ^rBioinformatics, Genomics England, Queen Mary University of London, London, United Kingdom; ^sMedicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee; ^tFundación Hipercolesterolemia Familiar, Madrid, Spain; ^uDepartment of Pediatrics (Cardiology), West Virginia University, Morgantown, West Virginia; ^vDepartment of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark; ^wDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ^xLipid Clinic Heart Institute (InCor) University of São Paulo Medical School Hospital and Hospital Israelita Albert Einstein, São Paulo, Brazil; ^yDepartment of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan; ^zDepartment of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; ^{aa}Department of Medicine, Division of Cardiology, Department of Genetics, McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri; ^{bb}Department of Cardiovascular Medicine, Rinku General Medical Center, Osaka, Japan; ^{cc}Departments of Community Medicine and Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; and the ^{dd}Departments of Genetics, Medicine, and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. *Ms. Sturm, Dr. Knowles, and Dr. Gidding contributed equally as first authors. †Ms. Wilemon, Dr. Ledbetter, and Dr. Rader contributed equally as last authors. Ms. Sturm has served on scientific advisory boards for Clear Genetics and Genome Medical. Dr. Knowles has served as the chief medical advisor for the Familial Hypercholesterolemia Foundation; and has received funding from an American Heart Association National Innovative Research Award and the Doris Duke Charitable Trust. Dr. Gidding has served as a consultant for Regenxbio. Dr. Ahmad has performed research for the National Institutes of Health and Regeneron; has served as a speaker for Amgen, Sanofi, and Akcea; and has served on advisory boards for Sanofi and Akcea. Dr. Ballantyne has received grant/research support (all paid to institution, not individual) from Abbott Diagnostic, Amarin, Amgen, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostics, and Sanofi-Synthelabo; and has served as a consultant for Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostics, and Sanofi-Synthelabo. Dr. Baum has served on scientific advisory boards, provided consulting, and performed clinical research for Amgen, Sanofi/Regeneron, Esperion, Akcea, AstraZeneca, Boehringer Ingelheim/Lilly, Novo Nordisk, and Gemphire;

Download English Version:

<https://daneshyari.com/en/article/8665825>

Download Persian Version:

<https://daneshyari.com/article/8665825>

[Daneshyari.com](https://daneshyari.com)